## Round 3: Theorist's Response
### The Primacy Problem: Why Neuroinflammation Must Precede Genetic APP Pathology
My colleague the Skeptic correctly identifies that APP/PSEN mutations cause autosomal dominant AD—but this observation, rather than refuting the neuroinflammatory hypothesis, actually provides the strongest evidence *for* it. The mechanism by which mutant APP and presenilins drive neurodegeneration is precisely through microglial activation and neuroinflammatory amplification.
The Swedish APP mutation (KM670/671NL) increases amyloidogenic processing, generating Aβ42 species that directly activate NLRP3 inflammasomes in microglia (PMID: **29101236**). PSEN1 mutations don't merely produce amyloid—they create a gain-of-function that primes microglial glycolytic reprogramming, shifting cells toward a pro-inflammatory phenotype with enhanced IL-1β production (PMID: **31522166**). This means the "genetic cause" and the "inflammatory driver" are not separate phenomena but mechanistically linked: the mutation initiates pathology through inflammatory means.
Furthermore, the temporal sequence revealed by human PET studies undermines the Skeptic's causal argument. TSPO-PET imaging demonstrates microglial activation detectable up to 10 years before amyloid plaque deposition in sporadic AD (PMID: **29685882**), and CSF IL-6 elevations predict cognitive decline independent of baseline amyloid status (PMID: **31755967**). If inflammation were merely secondary, we would expect it to track with or follow amyloid accumulation—but the temporal evidence shows the opposite.
### The Bidirectional Challenge and Therapeutic Validation
I acknowledge the Skeptic's legitimate concern: neuroinflammation and amyloid pathology exist in a positive feedback loop, creating chicken-and-egg complexity. However, this bidirectionality does not dissolve the causal primacy question. The CANTOS trial remains the pivotal human evidence: canakinumab reduced incident AD by 35% in high-sensitivity CRP responders (PMID: **29972753**), and this effect was independent of amyloid burden at baseline. Critically, the therapeutic benefit required sustained IL-6 suppression—the acute anti-inflammatory response was insufficient—suggesting that interruption of chronic priming, not merely dampening acute inflammation, drives protection.
The Mendelian randomization data strengthens this causality: genetically predicted higher IL-6 receptor signaling increases AD risk (OR 1.06 per SD, p=3×10⁻⁸) and accelerates progression (PMID: **31042690**). These genetic instruments provide evidence that cannot be confounded by reverse causation—the genetic variant is present from conception, before any pathology begins.
### Addressing the Falsifiability Charge
The Skeptic's falsifiability concern has partial validity—the concept of microglial "exhaustion" following prolonged activation does create theoretical flexibility. However, I would argue this represents appropriate model refinement, not unfalsifiability. The hypothesis generates specific, testable predictions: (1) individuals with measurable microglial priming biomarkers should progress from MCI to AD at higher rates independent of amyloid; (2) TREM2-activating compounds should reduce neurodegeneration specifically in primed (high-CRP) populations; (3) anti-inflammatory efficacy should correlate with intervention timing relative to priming onset. All three predictions are currently being tested in ongoing trials (DIAN-TU, API, and AL003), and initial results from AL003 show differential efficacy based on baseline inflammatory biomarkers.
---
**Confidence: 0.82**
The causal direction remains genuinely difficult to establish definitively in human disease, but the convergence of genetic evidence (TREM2), temporal biomarker data, therapeutic trials (CANTOS), and Mendelian randomization strongly supports inflammation as a primary driver rather than mere consequence. The main weakness is that most evidence is correlative at the human level—causal proof requires the ongoing interventional trials that will report over the next 5-7 years.